Cardiovascular disease remains a worldwide challenge, causing undue strain on the health system and contributing substantial patient burden. For decades, our medical response has been […]
Clinical development teams can use operational and institutional review board (IRB) data to identify protocol-design risks before those risks trigger
A note from Lauri Carlile, Chief Research Services Officer: For more than 40 years, Advarra’s institutional review board (IRB) has
Rethinking oversight as clinical trials become more data-driven and algorithm-informed As artificial intelligence (AI) becomes more embedded in clinical trial
Key takeaways from ‘The Operational Realities of Protocol Amendments’ panel discussion at the Advarra Innovation Summit in Research Triangle Park
Clinical trials are complex. That’s expected, given accelerated advancements in science and technology. But when that complexity creates friction in
Key takeaways from the Collaboration Lab Workshop at the Advarra Innovation Summit at Research Triangle Park 2026 One of the
Lori Young has spent her career at the intersection of research, ethics, and education—and her path to Advarra reflects both
AI is becoming a routine part of how research proposals are prepared and reviewed, from drafting applications to supporting administrative
Oncology research continues to push scientific boundaries, from biomarker-driven therapies to increasingly personalized treatment strategies. Operationally, however, many oncology trials
Oncology clinical trials are becoming increasingly complex, placing new operational and administrative demands on both sponsors and research sites. Protocols
Over the past 14 years, Anna Carnevale, associate director of client services at Advarra, has seen her team grow from
